Asthma and Allergy News and Research

Teva Launches AirDuo™ RespiClick® and its Authorized Generic

[Press Release] Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol First and Only Generic Fluticasone Propionate and Salmeterol (ICS/LABA) Inhaler Available in the U.S. JERUSALEM, April 20, 2017 – Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the simultaneous launch of AirDuo™ RespiClick® (fluticasone propionate and salmeterol) inhalation powder and its authorized generic for the treatment...

Asthma and Allergy Research Review January-March 2017

The Asthma and Allergy Foundation of America will recap some of the top research about allergies and asthma every three months. Here is a look at studies reported between January and March. Read about how treating homes for cockroaches can improve children's asthma, a possible link between insomnia and developing asthma, the safety of allergy immunotherapy and more.

GlaxoSmithKline Recalling Ventolin Inhalers for Possible Package Leakage

The Asthma and Allergy Foundation of America is a non-profit organization and we are reporting this recall to inform people with asthma who rely on this medication. If you have questions, call the GlaxoSmithKline response center, the manufacturer of Ventolin: 1-888-825-5249. GlaxoSmithKline (GSK) issued a voluntary Class II recall on April 4, 2017 for three lots of Ventolin® HFA 200D Inhalers from U.S. hospitals, pharmacies, retailers and wholesalers as a precautionary measure. It is not a...

New Eczema Drug Dupixent Approved by FDA

The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

GlaxoSmithKline Study Shows Nucala Improves Quality of Life, Lung Function in Severe Asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, when compared to patients treated with placebo and standard of care. These results are from the phase IIIb MUSCA study (NCT02281318, 200

Black Children Six Times More Likely to Die of Asthma

There is no cure for asthma, but with the proper diagnosis, medication and an asthma management plan, symptoms can be controlled. When not properly controlled asthma can be deadly. A study being presented at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting called “Where Do Children with Asthma Die? A National Perspective from 2003 to 2014” seeks to address where and which demographics of children are dying because of asthma in the United States.

Add Your Voice to Asthma Research

We know that everyone’s asthma is different and we would like to hear about your unique experiences about living with asthma. This research will give us insight on issues affecting quality of life and treatments for asthma. It will also help us raise awareness about living with asthma and improve our education materials. The My Life With Asthma online survey will take about 20 minutes to complete. Your identity and responses will be anonymous. After you take the survey, you can enter your...

Xyzal Allergy 24HR Approved for Over the Counter Use

Antihistamine Offers 24-Hour Relief to Adults and Children with Seasonal and Year-Round Allergies [Press Release] BRIDGEWATER, N.J. /PRNewswire/ -- Sanofi announced that the U.S. Food and Drug Administration (FDA) approved Xyzal® Allergy 24HR as an over-the-counter (OTC) treatment for the relief of symptoms associated with seasonal and year-round allergies. Specifically, two formulations of Xyzal are now approved for OTC use – 5 mg tablets for ages 6 years and older, as well as 0.5 mg/mL...

FDA Approves Spiriva Respimat to Treat Asthma In Children Ages 6-12

[Press Release] FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children Steroid-free SPIRIVA RESPIMAT now approved as asthma treatment for age 6 and older Supplemental New Drug Application (sNDA) approved under priority review from the FDA FDA also granted pediatric exclusivity to SPIRIVA RIDGEFIELD, Conn., Feb. 16, 2017 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and...

FDA Warns About Potential Allergic Reactions With the Skin Antiseptic Chlorhexidine Gluconate

The U.S. Food and Drug Administration (FDA) is warning that rare but serious allergic reactions have been reported with the widely used skin antiseptic products containing chlorhexidine gluconate. Although rare, the number of reports of serious allergic reactions to these products has increased over the last several years.

FDA Approves Two New Asthma Inhalers

[Press Release] Teva Announces FDA Approval of Two New RespiClick® Maintenance Inhalers for the Treatment of Asthma Approvals Expand Portfolio of Respiratory Medicines Delivered in RespiClick® Inhaler Designed to Eliminate the Need for Hand-Breath Coordination During Inhalation JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) approved two products for adolescent and adult patients with asthma.

×
×
×
×